✦ LIBER ✦

Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-hodgkin's lymphoma or multiple myeloma

✍ Scribed by Michael Steinberg; Matthew Silva

Book ID: 113544227
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 933 KB
Volume: 32
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2010.05.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for disease progressi

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

✍ Popat, U; Hosing, C; Saliba, R M; Anderlini, P; Besien, K van; Przepiorka, D; Kh 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 167 KB

Mobilization of peripheral blood stem ce

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients

✍ Fruehauf, S; Ehninger, G; Hübel, K; Topaly, J; Goldschmidt, H; Ho, A D; Müller, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 136 KB

Consolidative involved field radiotherap

Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study

✍ Christoph Oehler-Jänne; Christian Taverna; Nadine Stanek; Laura Negretti; Urs M. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

## Abstract The role of involved field radiation therapy (IF‐RT) after high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for non‐Hodgkin's lymphoma (NHL) has not been conclusively defined. It has been hypothesized that HDC might obviate the need of consolidative IF‐RT. A

High-dose methotrexate in the mobilizati

High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center

✍ Zhang, Cheng; Chen, Xing-Hua; Gao, Li; Liu, Yao; Gao, Lei; Kong, Pei-Yan; Zeng, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Treatment with Plerixafor in non-Hodgkin

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient

✍ Patrick Stiff; Ivana Micallef; Philip McCarthy; Margarida Magalhaes-Silverman; D 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 273 KB

Feasibility and Efficacy of High-Dose Me

Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin’s Lymphoma

✍ Li-na Han; Jin Zhou; Takayuki Hirose; Yosuke Imai; Takuro Ishiguro; Takaaki Chou 📂 Article 📅 2006 🏛 Carden Jennings Publishing 🌐 English ⚖ 137 KB